People: Shire PLC (SHPGF.PK)

SHPGF.PK on OTC Markets Group

31.05USD
17 May 2013
Price Change (% chg)

$-0.05 (-0.16%)
Prev Close
$31.10
Open
$31.05
Day's High
$31.05
Day's Low
$31.05
Volume
225
Avg. Vol
4,824
52-wk High
$33.80
52-wk Low
$27.39

Search Stocks

Summary

Name Age Since Current Position

Matthew Emmens

 61 2008 Non-Executive Chairman of the Board

Flemming Ornskov

 55 2013 Chief Executive Officer, Director

David Kappler

 65 2008 Senior Independent Non-Executive Deputy Chairman of the Board

Graham Hetherington

 54 2008 Chief Financial Officer, Executive Director

Jeff Jonas

 59 2012 President - Regenerative Medicine

Tatjana May

 47 General Counsel, Company Secretary

William Burns

 65 2010 Non-Executive Independent Director

Steven Gillis

 49 2012 Non-Executive Independent Director

David Ginsburg

 60 2010 Non-Executive Independent Director

Susan Kilsby

 54 2011 Non-Executive Independent Director

Anne Minto

 59 2010 Non-Executive Independent Director

David Stout

 58 2009 Non-Executive Independent Director
» Insider Trading

Biographies

Name Description

Matthew Emmens

 Mr. Matthew W. Emmens is Non-Executive Chairman of the Board of Shire Plc., since June 18, 2008. Mr. Emmens has been a member of the Board since March 12, 2003. He is also a member of the Nomination Committee. He was the Company’s Chief Executive Officer from March 2003 to June 2008. Mr. Emmens is a Director of Vertex Pharmaceuticals Inc. He served as Chairman, CEO and President of Vertex Pharmaceuticals Inc. from 2009 until early 2012 and is a former Director of Incyte Corporation. Mr. Emmens began his career in international pharmaceuticals with Merck & Co, Inc. in 1974, where he held a wide range of sales, marketing and administrative positions. In 1992, he helped to establish Astra Merck Inc., a joint venture between Merck and Astra AB of Sweden, becoming President and Chief Executive Officer. In 1999, he joined Merck KGaA and established EMD Pharmaceuticals, the company’s US prescription pharmaceutical business. He later served as President of Merck KGaA’s global prescription pharmaceuticals business in Germany. Mr. Emmens holds a degree in Business Management.

Flemming Ornskov

 Dr. Flemming Ornskov, M.D., MBA, MPH, has been appointed as Chief Executive Officer, Director of Shire Plc., effective April 30, 2013. Dr. Ornskov was appointed Chief Executive Officer Designate and a member of the Board on January 2, 2013. He is Non-Executive Chairman of Evotec AG and is a former Non-Executive Director of PCI Biotech Holding ASA. Dr. Ornskov held the position of Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer from 2010 to 2012. Prior to joining Bayer, Dr. Ornskov served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc., from 2008 to 2010. He also served as Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S from 2006 to 2008, and President and Chief Executive Officer of Ikaria, Inc., from 2005 to 2006. Earlier in his pharmaceutical career he had roles of increasing responsibility at Merck & Co. Inc. and Novartis AG, following a distinguished period in hospital and academic medicine. Dr. Ornskov received his MD from the University of Copenhagen, MBA from INSEAD, and Master of Public Health from Harvard University.

David Kappler

 Mr. David J. Kappler is Senior Independent Non-Executive Deputy Chairman of the Board of Shire Plc., since June 2008. Mr. Kappler has been a member of the Board since April 5, 2004. He was appointed Senior Independent Non-Executive Director in July 2007 and Deputy Chairman in June 2008. He is also Chairman of the Nomination Committee and of the Audit, Compliance & Risk Committee. He is a Non-Executive Director of InterContinental Hotels Group plc. He was Chairman of Premier Foods plc until September 2010 and held directorships at Camelot Group plc and HMV Group plc. Mr. Kappler retired from Cadbury Schweppes plc in April 2004 after serving as Chief Financial Officer since 1995. He worked for the Cadbury Schweppes Group between 1965 and 1984 and rejoined the company in 1989 following its acquisition of the Trebor Group, where he was Financial Director. Mr. Kappler is a Fellow of the Chartered Institute of Management Accountants.

Graham Hetherington

 Mr. Graham Hetherington is Chief Financial Officer, Executive Director of Shire Plc., since July 1, 2008. Mr. Hetherington has been the Chief Financial Officer and a member of the Board since July 1, 2008. He is also a member of the Leadership Team. Mr. Hetherington brings to his position, among other things, a broad range of international finance management and planning, audit, risk management and M&A experience. Mr. Hetherington most recently held positions as the Chief Financial Officer of Bacardi in 2007 and Chief Financial Officer of Allied Domecq plc from 1999 to 2005. Mr. Hetherington is a Fellow of the Chartered Institute of Management Accountants.

Jeff Jonas

 Dr. Jeff Jonas, M.D. has been appointed as President - Regenerative Medicine of Shire plc., effective November 15, 2012. On joining Shire, Dr. Jonas led the SP Research & Development team and was a member of the SP leadership team. Prior to joining Shire, he was Executive Vice President at Isis Pharmaceuticals. Previously, Dr. Jonas served as the Chief Medical Officer and Executive Vice President at Forest Laboratories. He began his career at Upjohn Laboratories. Dr. Jonas has also been a entrepreneur having founded cell therapy company AVAX Technologies, and co-founded biotech company, SCEPTOR Industries. Dr. Jonas received his MD from Harvard Medical School (Harvard University).

Tatjana May

 Ms. Tatjana May is General Counsel, Company Secretary of Shire Plc. She has been with Shire since May 2001. Ms. May was previously Assistant General Counsel at the corporate headquarters of AstraZeneca plc. Prior to that she worked at the law firm Slaughter and May.

William Burns

 Mr. William Burns is Non-Executive Independent Director of Shire Plc., since March 15, 2010. He was appointed to the Board on March 15, 2010 and is a member of the Remuneration Committee, the Nomination Committee and of the Science & Technology Committee. Mr. Burns brings to the Board experience in international sales, marketing, integration and operational experience in the pharmaceutical sector. He is a Director of Biotie Therapies Corp., Roche Holdings Ltd, Chugai Pharmaceutical Co., Ltd and Genentech, Inc. and is a former Director of Crucell N.V. Mr. Burns worked for many years for Roche, holding the position of CEO of their pharmaceuticals division from 2005 to 2009 and was a member of the Roche Group Corporate Executive Committee. Mr. Burns holds a BA (Hons).

Steven Gillis

 Dr. Steven Gillis, Ph.D. has been appointed as Non-Executive Independent Director of Shire plc., effective October 1, 2012. Dr. Gillis is a member of the Science & Technology Committee and the Remuneration Committee. Dr. Gillis is currently a Managing Director at ARCH Venture Partners, a provider of venture capital for technology firms, where he is focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. Prior to this, Dr. Gillis was a founder and director of Corixa Corporation, acquired by GlaxoSmithKline in 2005. Prior to starting Corixa, he was a founder and director of Immunex Corporation. An immunologist by training, Dr. Gillis has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Dr. Gillis received his BA from Williams College and his Ph.D. from Dartmouth College.

David Ginsburg

 Dr. David Ginsburg, M.D., is Non-Executive Independent Director of Shire Plc., since June 16, 2010. He is a member of the Science & Technology Committee. He is currently James V. Neel Distinguished University Professor of Internal Medicine Human Genetics, and Pediatrics at the University of Michigan and a Howard Hughes Medical Institute Investigator. Dr. Ginsburg obtained his BA at Yale University, MD at Duke University and completed his medical and research training at Harvard Medical School, before joining the faculty at the University of Michigan. Dr. Ginsburg is the recipient of numerous honors and awards, including election to membership in the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.

Susan Kilsby

 Ms. Susan Kilsby is Non-Executive Independent Director of Shire Plc., since September 1, 2011. Ms. Kilsby is a member of the Audit, Compliance & Risk Committee. She is a Non-Executive Director of BBA Aviation plc and was a Director of Hong Kong listed global skin care company, L’Occitane International S.A until December 2012. Ms. Kilsby has had a distinguished global career in investment banking having held senior positions with The First Boston Corporation, Bankers Trust, Barclays de Zoete Wedd and most recently Credit Suisse where she was Chairman of the EMEA Mergers & Acquisitions team until 2009 and continues in a part-time senior advisory capacity. Ms. Kilsby holds a BA in Economics and a MBA.

Anne Minto

 Ms. Anne Minto, OBE, is Non-Executive Independent Director of Shire Plc., since June 16, 2010. Ms. Minto is Chairman of the Remuneration Committee and a member of the Nomination Committee. She is a Non-Executive Director of Tate & Lyle PLC and is a former Director of Northumbrian Water plc and SITA UK. Ms. Minto held the position of Group Director, Human Resources at Centrica plc from October 2002 to 30 June 2011 and was a member of the Centrica Executive Committee. Her business career includes senior management roles at Shell UK, the position of Deputy Director-General of the Engineering Employers’ Federation and the position of Group Director Human Resources at Smiths Group plc. Following her law degree at Aberdeen University and a post graduate diploma in Human Resources she qualified as a lawyer. Ms. Minto is a Fellow of the Chartered Institute of Personnel & Development, the Royal Society of Arts and the London City and Guilds and a Member of Law Society of Scotland. She is a trustee of the University of Aberdeen Development Trust and is Patron of the University of Aberdeen Alumni Fund.

David Stout

 Mr. David M. Stout is Non-Executive Independent Director of Shire Plc., since October 31, 2009. Mr. Stout is a member of the Audit, Compliance & Risk Committee and of the Remuneration Committee. He is a Director of Jabil Circuit, Inc. and Airgas Inc. and is a former Director of Allos Therapeutics, Inc. Mr. Stout was President, Pharmaceutical Operations at GlaxoSmithKline, where he was responsible for the company’s global pharmaceutical operations, from January 2003 to February 2008. Prior to that, he was President of GlaxoSmithKline’s US Pharmaceuticals Business and before that SmithKline Beecham’s North American Pharmaceuticals Business. Before joining SmithKline Beecham, Mr. Stout worked for many years at Schering-Plough. Mr. Stout holds a BA in biology.

Basic Compensation

Name Fiscal Year Total

Matthew Emmens

 395,135

Flemming Ornskov

 --

David Kappler

 135,000

Graham Hetherington

 3,303,000

Jeff Jonas

 --

Tatjana May

 --

William Burns

 --

Steven Gillis

 --

David Ginsburg

 --

Susan Kilsby

 --

Anne Minto

 --

David Stout

 --
As Of 30 Dec 2012

Options Compensation

Name Options Value

Matthew Emmens

 1,557,715 7,803,879

Flemming Ornskov

 0 0

David Kappler

 0 0

Graham Hetherington

 0 0

Jeff Jonas

 0 0

Tatjana May

 0 0

William Burns

 0 0

Steven Gillis

 0 0

David Ginsburg

 0 0

Susan Kilsby

 0 0

Anne Minto

 0 0

David Stout

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks